Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AstraZeneca
AstraZeneca
Why the obesity drug market is about to get a lot more crowded
Medical Marketing and Media
Fri, 04/26/24 - 11:49 am
obesity
Novo Nordisk
Wegovy
Eli Lilly
Zepbound
Roche
AstraZeneca
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1
BioSpace
Thu, 04/25/24 - 05:56 pm
Sanofi
AstraZeneca
AstraZeneca leaps after smashing first-quarter forecasts
Reuters
Thu, 04/25/24 - 11:42 am
AstraZeneca
earnings
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027
Biopharma Reporter
Thu, 04/25/24 - 11:36 am
AstraZeneca
PARP inhibitors
Merck
Lynparza
ovarian cancer
AstraZeneca’s Tagrisso maintains momentum in NSCLC with FLAURA2 results
Clinical Trials Arena
Fri, 04/19/24 - 11:26 am
AstraZeneca
non-small cell lung cancer
Tagrisso
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Fierce Biotech
Thu, 04/18/24 - 11:11 am
M&A
biotech
AstraZeneca
Merck
Gracell
Harpoon Therapeutics
AstraZeneca Expands Fasenra’s Label to Younger Children with Severe Asthma
BioSpace
Fri, 04/12/24 - 11:15 am
AstraZeneca
Fasenra
severe asthma
FDA
eosinophilic asthma
pediatric
Shareholders approve AstraZeneca's 2024 pay proposal for CEO Pascal Soriot despite proxy adviser discontent
Fierce Pharma
Fri, 04/12/24 - 11:01 am
AstraZeneca
Pascal Soriot
Pharma CEOs
executive compensation
Leading AstraZeneca investor defends CEO pay ahead of shareholder vote
Fierce Pharma
Wed, 04/10/24 - 05:47 pm
AstraZeneca
Pascal Soriot
Pharma CEOs
executive compensation
7 Billion-Dollar Oncology M&As from Q1
BioSpace
Wed, 04/10/24 - 11:24 am
oncology
M&A
AbbVie
Immunogen
Bristol Myers Squibb
Mirati Therapeutics
RayzeBio
Novartis
MorphoSys
AstraZeneca
Fusion Pharmaceuticals
JNJ
Ambrx
Gracell
FDA grants accelerated approval to Enhertu for metastatic HER2-positive cancers
Investing.com
Sun, 04/7/24 - 04:45 pm
AstraZeneca
Daiichi Sankyo
FDA
Enhertu
solid tumors
AstraZeneca’s Imfinzi tackles another type of lung cancer with latest trial win
Fierce Pharma
Fri, 04/5/24 - 11:28 am
AstraZeneca
Imfinzi
clinical trials
limited-stage small cell lung cancer
Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24
Fierce Biotech
Wed, 04/3/24 - 11:36 am
biotech
M&A
IPOs
CG Oncology
Kyverna Therapeutics
Contineum Therapeutics
Boundless Bio
CymaBay Therapeutics
Gilead Sciences
MorphoSys
Novartis
Fusion Pharmaceuticals
AstraZeneca
Ambryx
JNJ
Inhibrix
Aventis
AZ, Daiichi Sankyo file Dato-DXd for second indication
Pharmaphorum
Tue, 04/2/24 - 11:31 am
AstraZeneca
Daiichi Sankyo
Dato-DXd
breast cancer
AstraZeneca CEO's 2024 pay proposal under fire from influential proxy advisers
Fierce Pharma
Mon, 04/1/24 - 11:18 pm
AstraZeneca
Pascal Soriot
Pharma CEOs
executive compensation
AstraZeneca Gets FDA Approval in Boost to Rare Disease Franchise
BioSpace
Mon, 04/1/24 - 11:58 am
AstraZeneca
FDA
rare disease
danicopan
PNH
AstraZeneca CEO ‘deeply humbled’ by award recognizing pandemic efforts
Biopharma Reporter
Thu, 03/28/24 - 11:18 am
AstraZeneca
Pharma CEOs
Pascal Soriot
vaccines
COVID-19
Brainomix AI shows its worth in AZ pulmonary fibrosis trial
Pharmaphorum
Wed, 03/27/24 - 10:55 am
AstraZeneca
Brainomix
tralokinumab
IPF
artificial intelligence
Big Pharma CEOs gather in Beijing to show continued interest in China, offer policy advice
Fierce Pharma
Tue, 03/26/24 - 04:26 pm
China
Pharma CEOs
AstraZeneca
Bayer
Bristol Myers Squibb
GSK
Novartis
Pfizer
Takeda
AstraZeneca’s rare disease unit overcomes FDA snub to expand Ultomiris in NMOSD
Fierce Pharma
Mon, 03/25/24 - 10:31 pm
AstraZeneca
Soliris
NMOSD
Ultomiris
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »